Sanofi - Corporate Presentation

2015 I CORPORATE PRESENTATION

HOPE, it’s what Sanofi brings each day, responding to the new challenges of protecting the health of seven billion people

VIDEO HOPE

© Denis FelixJune 11, 2015

https://www.youtube.com/watch?v=WtF7xtYa0VA

SANOFI AT A GLANCEOUR HERITAGE

OUR STRATEGY

OUR COMMITMENTS

OUR 3 BUSINESS SEGMENTS

OUR INNOVATION IN R&D

OUR RESPONSIBILITY

OUR KEY FIGURES

OUR PRESENCE

CORPORATE PRESENTATION – JUNE 11, 2015 2

SANOFI AT A GLANCE

3

© Denis Felix

CORPORATE PRESENTATION – JUNE 11, 2015

SANOFI AT A GLANCE

OUR HERITAGE

A long tradition in health

4

HoechstMarion Roussel

1997

Roussel1911

Marion1950

Hoechst1863

Synthélabo1970

Delalande1924

Delagrange1931

Robert & Carrière

1901

Dausse1834

BMP Sunstone, Medley,Merial, Nepentes, Zentiva,

Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha Biotechnics , Fovea, Bipar

Sciences, Targegen, Genfar, Globalpharma

2008-2015

Genzyme2011

Sanofi-aventis2004

Aventis1999

Sanofi-Synthélabo1999

Sanofi Pasteur2004

Sterling1901

Midy1718

Clin Midy1971

Chinoin1919

Sanofi1973

Connaught1922

Rorer1910

Rhône-Poulenc Rorer1990

Institut Mérieux

1897

Wittman & Poulenc

1860


SANOFI AT A GLANCE

OUR STRATEGY

5

SEIZEVALUE-ENHANCINGGROWTH OPPORTUNITIES

ADAPTSTRUCTURE FORFUTURE CHALLENGES & OPPORTUNITIES

BRINGINNOVATIVE PRODUCTSTO MARKET

Delivering sustainable long-term growth by:

GROWA GLOBAL HEALTHCARELEADER WITH SYNERGISTIC PLATFORMS

© Guillaume Ramon/Capa Pictures


SANOFI AT A GLANCE

6

Our missionWe act with our partner to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the world.

3 business segments

Pharma Human vaccines

Animal Health

3 CommitmentsExploring the boundaries of medical innovation for patients

Preventing disease and supporting patients

Improving access to healthcare

More than

110,000employees

Present in

100countries

€33.8 bnIn sales 2014


SANOFI AT A GLANCE

OUR MISSION

We act with our partners to protect health, enhance life, provide hope and respond to the potential healthcare needs of 7 billion people around the world.

With our global footprint and commitment to improving access to medicines and healthcare, we work tirelessly to make a difference to people’s lives every day and transform scientific innovations into therapeutic solutions for patients.

7

© G. Blonsky/Capa Pictures


SANOFI AT A GLANCE

OUR COMMITMENTS

8

1

EXPLORING THE BOUNDARIES OF MEDICAL INNOVATION

Sanofi is committed to a more open and productive Research & Development model, focused on patient needs and based on biotechnology. This model significantly accelerates the pace and enhances the productivity of research, driving the development of more effective health solutions in major therapeutic areas.

Between 2014 and 2020, more than 18 potential launches are anticipated.

© Pierre-Olivier/Capa Pictures


SANOFI AT A GLANCE

OUR COMMITMENTS

9

2

PREVENTING DISEASES AND SUPPORTING PATIENTS

Improved quality of life and longer life expectancy, coupled with increased prevalence of chronic disease are contributing to the evolution of today’s main healthcare challenges.

Sanofi promotes prevention through vaccination and support for patients.

The Group’s commitment goes beyond a medication: it is based on understanding and listening to patients to provide integrated health solutions and personalized treatment.

© Pierre-Olivier/Capa Pictures


SANOFI AT A GLANCE

© Denis Felix

OUR COMMITMENTS

10

3

IMPROVING ACCESS TO HEALTHCAREHealthcare needs vary from continent to continent. While the northern hemisphere is marked by an aging population, the southern is characterised by demographic growth, urbanization, and a rise in chronic diseases.

To meet the many different healthcare needs of the seven billion inhabitants of our planet and improve their access to treatment, Sanofi has established a global presence in more than 100 countries, a specific product portfolio for each market and a leadership position in Emerging markets.


SANOFI AT A GLANCE

OUR3 BUSINESS SEGMENTS

11

HUMAN VACCINES>Pediatric vaccines

> Influenza vaccines

>Booster vaccines for adults and adolescents

>Meningitis vaccines

>Vaccines for travelers and endemic areas

ANIMAL HEALTHPHARMA PRODUCTS

>Anti-parasitics

>Anti-infectives

>Anti-inflammatories

>Anti-ulceratives

VACCINES

>Foot and mooth disease

>Rabies and pets vaccines Range

>Avian vaccines

PHARMA

>Diabetes

>Cardiovascular disease

>Rare diseases

>Multiple sclerosis

>Oncology

>Consumer Health care

>Generics

Net sales€27,720 M

Net sales€3,974 M

Net sales€2,076 M

© G. Blonsky/Capa Pictures


SANOFI AT A GLANCE

OUR INNOVATION IN R&D

12

€4.8bnInvested in R&D in 2014

5R&D HUBS Across Europe, North America and Asia-Pacific

43molecules and vaccines in the R&D portfolio including 14 in late stage*

Up to 18 launches expected between 2014 and 2020

*Annual results, Feb. 2015

Diabetes ToujeoAfrezzaLixilan

LyxumiaInsulin pro

Uncontrolled Hypercholesterolemia

Praluent®

PediatricVaccines

Shan 5PR5i-6-1

Rotavirus vaccine

Rare diseaseFamilial amyloidpolyneuropathy

Patisiran

Dengue Dengue vaccine

Clostridum Difficile C.Diff vaccine

Multiple Sclerosis Lemtrada

Oncology SAR650984

Type 1 Gaucher disease

Cerdelga

Severe asthma dupilumab

Dogs Fleas and ticks Nexgard®

Rheumatoid arthritis sarilumab


SANOFI AT A GLANCE

CORPORATESOCIALRESPONSIBILITY

13

© Pierre–Olivier/Capa Pictures

Each day, across the globe, Sanofi’s 110,000 employees are working to protect the health and improve access to healthcare for as many patients as possible.

As a healthcare company, Sanofi places quality, safety, ethics, and respect for the planet at the heart of its business.

More than300 access to healthcare programs in more than 80 countries

1/3 of the global population has no access to healthcare

More than190 millionpeople benefited

PARTNERING TO PROMOTE ACCESS TO HEALTHCARE


SANOFI AT A GLANCE

14

Improve access to medicines in the most deprived countries with an access to medicines department whose holistic approach acts on several levels:

> Tiered-pricing for affordable medicines

> Information, training and education programs

> Innovative research

> Partnerships on the ground to ensure program success

Reduce health inequalitiesthrough its ’programs dedicated to:

> Childhood cancer

> Maternal and neonatal mortality

> Access to healthcare for the world’s most needy communities.

Promoting quality care by fighting against counterfeit medicines.

CORPORATESOCIALRESPONSIBILITY

© Rémi DUHAMEL - Image in Production


SANOFI AT A GLANCE

OURKEY FIGURES 2014

15

BY ACTIVITIES(in million euros)

BY GEOGRAPHICAL AREA(in million euros)

EMPLOYEES BY ACTIVITIES

EMPLOYEES BY GEOGRAPHICAL AREA

€33.8 bnNet sales

Animal Health2,076

Pharma27,720

Vaccines3,974

More than

110,000employees worldwide

United States11,339

Other countries3,219

Emerging markets11,347

Western Europe7,865

Animal Health6,109

Pharma93,393

Vaccines13,994

Other countries41,528

North America18,627Europe

53,341

Emerging Markets: The world excluding the United States, Canada, Western Europe, Japan, Australia and New Zealand.


SANOFI AT A GLANCE

OUR PRESENCE

16

In more than 100 countries

107Industrial sitesin 40 countries

More than

20R&D sites worldwide

CLOSER TO OUR PATIENTS AND PARTNERS

EUROPE48

Manufacturing sites6

Development centers33

Distribution HubsNORTH AMERICA

19 Manufacturing sites

2 Development centers

8 Distribution Hubs

ASIA-PACIFIC20



Distribution Hubs

LATIN AMERICA12



Distribution Hubs

AFRICA-MIDDLE-EAST8


Development center58

Distribution Hubs


RECOMMENDATIONS

Forward Looking Statements

This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

17

This corporate presentation is available for all employees of the Sanofi Group. It may be used internally or externally for presentations of the Group, either in whole or in part, as needed.

The information is taken from Sanofi’s annual report on Form 20-F 2014, annual results 2014 and press releases.

Further information is available on www.sanofi.com


Further information:www.sanofi.com

SANOFICOMMUNICATION CORPORATE 54, rue La Boétie 75008 Paris, FranceTel. +33 (0)1 53 77 40 00

CORPORATE PRESENTATION 2015 18

Health & Medicine

Sanofi - Corporate Presentation